Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.

Front ImmunolAug 31, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Yici Yan, Weidong Gao, Zhenzheng Zhu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of bispecific antibodies (BsAbs) in treating solid tumors, involving 3,505 patients across 9 studies. BsAbs significantly improved progression-free survival (PFS) with a hazard ratio of 0.76 and overall survival (OS) with a hazard ratio of 0.78 compared to other antitumor therapies.

Key findings

  • BsAbs improved progression-free survival (HR: 0.76, 95% CI: 0.61-0.94, p=0.011).
  • BsAbs also enhanced overall survival (HR: 0.78, 95% CI: 0.63-0.95, p=0.016).
  • The overall response rate showed a borderline effect (RR: 1.20, 95% CI: 1.00-1.44, p=0.046).
  • Increased adverse events included renal and vascular toxicities, as well as immune-related toxicities.

Why it matters

The findings suggest that bispecific antibodies may offer significant survival benefits for patients with solid tumors, highlighting their potential as a valuable treatment option. Understanding their safety profile is crucial for clinicians when considering treatment plans.

Source

PubMed · PMID 42694493Free full text on PubMed Central

Published in Front Immunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.